Market research
29T.F TherapeuticsMD, Inc
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 949K
- P/E ratio
- Not available
- Analyst target
- 5.8
- Dividend yield
- 0.0%
- Beta
- 1.9
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 949K
- P/E ratio
- Not available
- Analyst target
- 5.8
- Dividend yield
- 0.0%
- Beta
- 1.9
About
About TherapeuticsMD, Inc
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 29T.F discussion.
5 years, 5 months ago
TherapeuticsMD, Inc is currently in a long term downtrend where the price is trading 18.9% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.7.
TherapeuticsMD, Inc's total revenue rose by 42.0% to $23M since the same quarter in the previous year.
Its net income has increased by 14.9% to $-42M since the same quarter in the previous year.
Finally, its free cash flow grew by 57.4% to $-30M since the same quarter in the previous year.
Based on the above factors, TherapeuticsMD, Inc gets an overall score of 4/5.